Cheilbio Co., Ltd. Share Price

Equities

A052670

KR7052670007

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 19/07/2023 BST 5-day change 1st Jan Change
2,080 KRW -9.96% Intraday chart for Cheilbio Co., Ltd. -.--% -.--%

Financials

Sales 2022 15.35B 11.13M 888M Sales 2023 12.11B 8.78M 701M Capitalization 56.18B 40.73M 3.25B
Net income 2022 -1.71B -1.24M -98.82M Net income 2023 -1.45B -1.05M -83.66M EV / Sales 2022 0.75 x
Net cash position 2022 22.09B 16.01M 1.28B Net cash position 2023 19.83B 14.37M 1.15B EV / Sales 2023 3 x
P/E ratio 2022
-20 x
P/E ratio 2023
-38.5 x
Employees 76
Yield 2022 *
-
Yield 2023
-
Free-Float 67.43%
More Fundamentals * Assessed data
Dynamic Chart
Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cheilbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on April 13, 2022. CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on April 13, 2022. CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on April 13, 2022. CI
Cheilbio Co., Ltd.'s Equity Buyback announced on April 13, 2022, has expired with 1,246,452 shares, representing 4.41% for KRW 2,999.36 million. CI
Cheilbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Cheilbio Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares. CI
Cheilbio Co., Ltd. authorizes a Buyback Plan. CI
Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on March 23, 2018. CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on March 23, 2018. CI
Cheilbio Co., Ltd.'s Equity Buyback announced on March 23, 2018 has expired with 495,436 shares for KRW 1,984.53 million. CI
Tranche Update on Cheilbio Co., Ltd.'s Equity Buyback Plan announced on March 23, 2018. CI
More news
1 year
1 555.00
Extreme 1555
2 605.00
3 years
1 131.00
Extreme 1131
4 530.00
5 years
1 131.00
Extreme 1131
5 825.00
10 years
1 131.00
Extreme 1131
5 825.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 84 -
Comptroller/Controller/Auditor 36 -
Comptroller/Controller/Auditor 81 -
Members of the board TitleAgeSince
Chief Executive Officer 84 -
Director/Board Member 57 -
Director/Board Member 49 -
More insiders
Cheilbio Co., Ltd. is a Korea-based company engaged in the manufacturing of veterinary drugs. The Company's offerings consist of antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits including enzyme-linked immunosorbent assay (ELISA) test kits, virus test kits and deoxyribonucleic acid (DNA) kits, as well as feed additives. The Company’s products are used for cattle, pigs, chickens, pets and other animals. It supplies its products mainly to the domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. A052670 Stock